Indian markets remained bearish for the the second consecutive week ended May 13 as the benchmark share indices lost nearly 4 percent. Persistent worries over rising inflation, possibility of further rate hikes by global central bank, China lockdown and weakening rupee kept the investors on the edge. During the last week, BSE Sensex declined 2,041.96 points (3.72 percent) to close at 52,793.62, while the Nifty50 shed 629.05 points (3.83 percent) to end at 15,782.20 levels. However, in the month of May Sensex and Nifty have lost more than 7 percent each. During the week gone by, all the sectoral indices were in the red with BSE Metal and Power indices falling 13 percent each. BSE Telecom index shed 6.7 percent and Realty index declined 5.8 percent. In broader market, the BSE Mid-cap index lost 5.6 percent, Small-cap index shed 6.5 percent and Large-cap Index declined 4.4 percent. In absence of any major event, market participants will be closely eyeing the performance of … [Read more...] about Dalal Street Week Ahead | LIC listing, earnings among 10 key factors that will keep traders busy
Glaxosmithkline gsk
WHO Endorses Pfizer’s Antiviral Pill Paxlovid For High-Risk Covid Patients But Says Benefits ‘Trivial’ For Low-Risk Groups
Share to Twitter Share to Linkedin Topline The World Health Organization has recommended Pfizer’s antiviral pill Paxlovid to treat high-risk Covid patients, the agency announced Friday, which it said is safer, easier to administer and better at preventing hospitalizations than other available treatments. Key Facts The WHO’s expert panel endorsed Paxlovid—a combination of nirmatrelvir, which inhibits coronavirus replication, and ritonavir, an HIV inhibitor which also slows the liver’s breakdown of nirmatrelvir—for Covid patients without severe disease who are at high risk of hospitalization. High risk groups include older patients, those with compromised immune systems or chronic illnesses and the unvaccinated, according to the guidelines. The panel cited new data from two clinical trials involving 3,100 patients, which found Paxlovid led to 84 fewer hospital admissions per 1,000 patients treated with little or no risk of severe side effects … [Read more...] about WHO Endorses Pfizer’s Antiviral Pill Paxlovid For High-Risk Covid Patients But Says Benefits ‘Trivial’ For Low-Risk Groups